Abstract
The addition of rituximab (R) to CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) -like therapy has improved survival in primary mediastinal B-cell lymphoma (PMBCL) patients. However, these results were obtained in young low risk patients and a reevaluation in an unselected patient cohort is warranted. In this study, we analyzed 80 PMBCL patients treated with a CHOP-based regimen with and without rituximab. In the non-rituximab cohort 10-year progression free survival (PFS) was 67% and 10-year overall survival (OS) was 72% versus a PFS of 95% and a OS of 92% in the rituximab group, PFS P = 0.001, OS P = 0.023. A subgroup PFS analysis by international prognostic index (IPI) risk revealed that all risk groups benefit from addition of rituximab to induction chemotherapy. In addition, OS probability was higher in the group of non-low risk patients who were treated with rituximab compared to those patients who did not receive rituximab (P = 0.035). In multivariate analysis, only addition of rituximab to induction chemotherapy and reaching complete remission (CR) after first line therapy had a beneficial effect on both PFS and OS, whereas IPI, age, upfront high dose (HD) chemotherapy/autologous blood stem cell transpl...Continue Reading
References
Sep 30, 1993·The New England Journal of Medicine·UNKNOWN International Non-Hodgkin's Lymphoma Prognostic Factors Project
Apr 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M LazzarinoP Möller
Nov 18, 1998·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M P MartelliF Mandelli
Mar 10, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A A Abou-ElellaJ O Armitage
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B D ChesonG P Canellos
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P C BishopP C Elwood
Jan 22, 2004·British Journal of Cancer·G TodeschiniG Pizzolo
Aug 24, 2005·British Journal of Haematology·Paul A HamlinCraig H Moskowitz
Aug 21, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M RiegerUNKNOWN MabThera International Trial (MInT) Group
Jan 26, 2011·Leukemia & Lymphoma·Wai Meng TaiSoon Thye Lim
Feb 9, 2011·Blood·Elias CampoElaine S Jaffe
Jan 28, 2012·The Oncologist·Theodoros P VassilakopoulosMaria K Angelopoulou
Nov 22, 2012·The Lancet Oncology·Norbert SchmitzUNKNOWN German High-Grade Lymphoma Study Group (DSHNHL)
Dec 19, 2012·International Journal of Radiation Oncology, Biology, Physics·Li-Ming XuJian-Rong Dai
Apr 12, 2013·The New England Journal of Medicine·Kieron DunleavyWyndham H Wilson
Jun 6, 2013·Leukemia & Lymphoma·Jacob D SoumeraiJeremy S Abramson
Jul 19, 2013·The New England Journal of Medicine·Wyndham H WilsonKieron Dunleavy
Jul 19, 2013·The New England Journal of Medicine·Amanda F CashenNancy L Bartlett
Mar 7, 2014·Annals of Hematology·Abraham AvigdorArnon Nagler
Apr 29, 2015·Cancer Treatment Reviews·Vijaya Raj BhattJames O Armitage
Oct 10, 2015·British Journal of Haematology·Mathias Witzens-HarigAnthony D Ho
Citations
Dec 7, 2018·Journal of Zhejiang University. Science. B·Yu-Chen LinKe Yao
Jul 3, 2019·Cancer Medicine·Esther Hian Li ChanLi Mei Michelle Poon
Dec 22, 2017·British Journal of Haematology·Nirav N ShahJakub Svoboda
Dec 7, 2018·The British Journal of Radiology·Yijing XieJunlin Zhou
Apr 20, 2021·The Oncologist·Theodoros P VassilakopoulosGerassimos A Pangalis
Oct 1, 2021·Thoracic Cancer·Yating YuHuaquan Wang
Nov 25, 2021·Cancer Medicine·Yael MorgensternNetanel A Horowitz